Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2003-06-30
2009-12-15
Graser, Jennifer E (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S185100, C424S190100, C424S241100, C424S261100, C530S350000
Reexamination Certificate
active
07632513
ABSTRACT:
An immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment thereof or the amino acid sequence of subunit A of anEscherichia coliheat labile toxin (LT-A) or a fragment thereof wherein the amino acids at, or in positions corresponding to Ser-63 and Arg-192 are replaced with another amino acid. The immunogenic detoxified protein is useful as vaccine forVibrio choleraeor an enterotoxigenic strain ofEscherichia coliand is produced by recombinant DNA means by site-directed mutagenesis.
REFERENCES:
patent: 4328209 (1982-05-01), Finkelstein et al.
patent: 4666837 (1987-05-01), Harford et al.
patent: 4935364 (1990-06-01), Kaper et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5601827 (1997-02-01), Collier et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5770203 (1998-06-01), Burnette et al.
patent: 6019982 (2000-02-01), Clements et al.
patent: 6033673 (2000-03-01), Clements
patent: 6149919 (2000-11-01), Domenighini et al.
patent: 0396964 (1990-11-01), None
patent: 0462534 (1991-12-01), None
patent: 9320454.3 (1994-10-01), None
patent: 9324743.5 (1994-10-01), None
patent: WO 92/19265 (1992-11-01), None
patent: WO 93/13202 (1993-07-01), None
patent: WO 95/09649 (1995-04-01), None
patent: WO 95/34323 (1995-12-01), None
patent: WO 96/06627 (1996-03-01), None
patent: WO 99/58145 (1999-11-01), None
patent: WO 00/18434 (2000-04-01), None
Mikayama et al. (Nov. 1993. Proc.Natl.Acad.Sci. USA, vol. 90 : 10056-10060).
Rudinger et al. (Jun. 1976. Peptide Hormones. Biol.Council. pp. 5-7).
Burnette, “The Advent of Recombinant Pertussis Vaccines.”Biotechnol. 8:1002-1005 (1990).
Burnette,Vaccine Research&DevelopmentsMarcel Dekker Inc., New York, New York (1992).
Clements, et al.. “Adjuvant Activity ofEscherichia coliHeat-Labile Enterotoxin and Effect on the Induction of Oral Tolerance in Mice to Unrelated Protein Antigens.”Vaccine6:269-277 (1988).
Communication to EPO Concerning Replacement Claims for Filing with the EPO in Application No. 99922284.7 (2003).
de Haan, et al.. “Mutational Analysis of the Role of ADP-Ribosylation Activity in the Adjuvant Properties of theEscherichia coliHeat-Labile Enterotoxin Towards Intranasally Administered Keyhole Limpet Hemocyanin.”Eur. J. Immunol. 28:1243-1250 (1998).
Del Guidice, et al.,“Genetically Derived Toxoids for use as Vaccines and Adjuvants.”Vaccine17:S44-S52 (1999).
Douce, et al.,“Mutants ofEscherichia coliHeat-Labile Toxin Lacking ADP-Ribosyltransferase Activity act as Nontoxic, Mucosal Adjuvants.”PNAS USA92:1644-1648 (1995).
Douce, et al., “Intranasal Immunogenicity and Adjuvanticity of Site Directed Mutant Derivatives of Cholera Toxin.”Infect. Immun. 65:2821-2828 (1997).
EPO Communication pursuant to Article 96(2) EPC relating to Application EP No. 94928455.8-2116 (2001).
“Multicomponent Vaccine Development.”NIH Guidevol. 22, No. 28 (1993).
Green, Bruce, Curriculum Vitae.
Hagen, Michael, Curriculum Vitae.
Hagiwar, et al.. Effectiveness and Safety of MutantEscherichia coliHeat-Labile Enterotoxin (LT H44A) as an Adjuvant for Nasal Influenza Vaccine.Vaccine19:2071-2079 (2001).
Hartman, et al.,“Native and Mutant Forms of Cholera Toxin and Heat-Labile Enterotoxin Effectively Enhance Protective Efficacy of Live Attenuated and Heat-Killed Shigella Vaccines.”Infect. Immun. 67:5841-5847 (1999).
Hazama, et al.. “Intranasal Immunization Against Herpes Simplex Virus Infection by using a Recombinant Glycoprotein D Fused with Immunomodulating Proteins, the B Subunit ofEscherichia coliHeat-Labile Enterotoxin and Interleukin-2.”Immunology78:643-649 (1993).
Hirst, et al.. “Cholera Toxin and Related Enterotoxins as Potent Immune Modulators.”J. Appl. Microb. Symp. Suppl. 48:26S-34S (1998).
Hirst,The Comprehensive Sourcebook of Bacterial Protein Toxins, Chapter 6, Academic Press, pp. 104-130, (1999).
Holmgren, et al., “Cholera Toxin and Cholera B Subunit as Oral-Mucosal Adjuvant and Antigen Vector Systems.”Vaccine11:1179-1184 (1993).
Lycke, et al.,“Strong Adjuvant Properties of Cholera Toxin on Gut Mucosal Immune Responses to Orally Presented Antigens.”Immunol. 56:30l-308 (1986).
Lycke, et al, “The Mechanism of Cholera Toxin Adjuvanticity.”Res. Immunol. 198:504-520 (1997).
Martindale,Royal Pharmaceutical Society of Britain Pharmaceutical Press, London, England, pp. 1277-1304(1993).
Rappouli, et al., “Structure and Mucosal Adjuventicity of Cholera andEscherichia coliHeat-Labile Enterotoxins.”Immunol. Today20:493-500 (1999).
Spangler, “Structure and Function of Cholera Toxin and The RelatedEscherichia coliHeat-Labile Enterotoxin.”Microbiol. Rev. 56:622-647 (1992).
Streatfield, et al. ,“Intermolecular Interactions Between the A and B Subunits of Heat-Labile Enterotoxin fromEscherichia coliPromote Holotoxin Assembly and Stability In Vivo.”PNAS USA89:12140-12144 (1992).
The Comprehensive Sourcebook of Bacterial Protein Toxins, 2ndEd., Academic Press, pp. 696-697.
Tsuji, et al.. “Relationship Between a Low Toxicity of the Mutant A Subunit of EnterotoxigenicEscherichia coliEnterotoxin and its Strong Adjuvant Action.”Immunology90:176-182 (1997).
Verweji, et al.,Mucosal Immunoadjuvant Activity of RecombinantEscherichia coliHeat-Labile Entertoxin and its B Subunit: Induction of Systematic IgG and Secretory IgA Responses in Mice by Intranasal Immunization with Influenza Virus Surface Antigen.Vaccine16:2069-2076 (1998).
Walker et al., “Use of Heat-Labile Toxin EnterotoxigenicEscherichia colito Facilitate Mucosal Immunization.”Vaccine Res. 2:1-10 (1993).
Williams, Neil, Affidavit, Curriculum Vitae, and Annex 1.
Yamamoto, et al., “Mutants in the ADP-Ribosyltransferase Cleft of Cholera Toxin Lack Diarrheagenicity but Retain Adjuvanticity.”J. Exp. Med. 185:1203-1210 (1997).
Boslego, J.W. et al., Vaccines and Immunotherapy, Chapter 17, 1991, 211-223.
Burnette, W.N. et al., “Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity,”Inf.&Immun., 1991,59:4266-4270.
Dallas, W.S. et al., “Cistrons encodingEscherichla coilheat-labile toxin,”J. Bacteriol, 1979, 139:850-858.
Dente, L. et al., “pEMBL: a new family of single stranded plasmids,”Nucleic Acids Res., 1983 11(6):1645-1655.
Domenighini, M. et al., “Identification of errors among database sequence entries and comparison of correct amino acid sequences for the heat-labile enterotoxins ofEschericia coliandVibrio cholerae,” Mol. Microbiol., 1995, 15(6):1165-1167.
Domenighini, M. et al., “Common features of the DNA-binding and catalytic site of ADP-ribosylating toxins,”Mol. Microbiol., 1994, 14(1):41-50.
Dickinson, B. et al., “Dissociation ofEscherichia coliheat-labile enterotoxin adjuvanticity from ADP-ribosykransferase activity,”Infection and Immunity, 1995, 63(5):1617-1623.
Donta, S., “Detection of heat-labileEscherichia colienterotoxin with the use of adrenal cells in tissue culture,”Science,1974, 183:334-336.
Fontana, M.R. et al., “Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit,”Infection and Immunity, 1995, 63(6):2356-2360.
Grant, C. et al., “Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities ofEscherichia coliheat-labile enterotoxin,”Infection and Immunity, 1994, 62(10):4270-4278.
Grant, C.C.R. et al., “Effect of single amino acid changes on the ADP-ribosyltransferase activity ofEscherichia coliheat-labile toxin subunit A,” 92ndGen. Meet. Am. Soc. Microbiol., 1992, Abstract B278, 74.
Harford, S. et al., “Inactivation of theEscherichia coliheat-labile enterotoxin by in vitro mutagenesis of the A-subunit gene,”Eur. J. Biochem., 1989,183:311-316 .
Hase, C. e
Fontana Maria Rita
Giannelli Valentina
Pizza Mariagrazia
Rappuoli Rino
Gorman Robert
Graser Jennifer E
Lee Helen
Novartis Vaccines and Diagnostics SRL
LandOfFree
Immunogenic detoxified mutants of cholera toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic detoxified mutants of cholera toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic detoxified mutants of cholera toxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4104375